Pharmacotherapy for Anxiety Disorders: From First-Line Options to Treatment Resistance

Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders

Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090 · see citing works

Network meta-analysis: an introduction for clinicians

Rouse, B., Chaimani, A., & Li, T. (2017) · Internal and Emergency Medicine · doi:10.1007/s11739-016-1583-7 · Cited by 875 · see citing works

Treatment of Endogenous Anxiety With Phobic, Hysterical, and Hypochondriacal Symptoms

Sheehan, D. V. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780140053006 · Cited by 728 · see citing works

Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial

Clark, D. M., Ehlers, A., McManus, F., Hackmann, A., Fennell, M., Campbell, H., Flower, T., Davenport, C., & Louis, B. (2003) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.71.6.1058 · Cited by 561 · see citing works

Mechanism of action of serotonin selective reuptake inhibitors

Stahl, S. M. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00221-3 · Cited by 540 · see citing works

Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction.

Montejo, A. L., Llorca, G., Izquierdo, J. A., & Rico‐Villademoros, F. (2001) · PubMed · Cited by 460 · see citing works

Phenelzine vs Atenolol in Social Phobia: A Placebo-Controlled Comparison

Liebowitz, M. R., Schneier, F., Campeas, R., Hollander, E., Hatterer, J., Fyer, A., Gorman, J., Papp, L., Davies, S., Gully, R., et al. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.49.4.290 · Cited by 444 · see citing works

Fluoxetine, Comprehensive Cognitive Behavioral Therapy, and Placeboin Generalized Social Phobia

Davidson, J. R. T., Foa, E. B., Huppert, J. D., Keefe, F. J., Franklin, M. E., Compton, J. S., Zhao, N., Connor, K. M., Lynch, T. R., & Gadde, K. M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.10.1005 · Cited by 415 · see citing works

Antidepressants for the Treatment of Generalized Anxiety Disorder

Rickels, K. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820230054005 · Cited by 412 · see citing works

Treatment of Social Phobia With Gabapentin

Pande, A. C., Davidson, J. R. T., Jefferson, J. W., Janney, C. A., Katzelnick, D. J., Weisler, R. H., Greist, J. H., & Sutherland, S. M. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199908000-00010 · Cited by 392 · see citing works

Pharmacotherapy of Social Phobia

Versiani, M., Nardi, A. E., Mundim, F. D., Alves, A. B., Liebowitz, M. R., & Amrein, R. (1992) · The British Journal of Psychiatry · doi:10.1192/bjp.161.3.353 · Cited by 333 · see citing works

Imipramine and Chlordiazepoxide in Depressive and Anxiety Disorders

Kahn, R. J. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800010081010 · Cited by 278 · see citing works

Placebo-Controlled Study of Gabapentin Treatment of Panic Disorder

Pande, A. C., Pollack, M. H., Crockatt, J. G., Greiner, M., Chouinard, G., Lydiard, R. B., Taylor, C. B., Dager, S. R., & Shiovitz, T. M. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200008000-00011 · Cited by 276 · see citing works

Hydroxyzine for generalised anxiety disorder

Guaiana, G., Barbui, C., & Cipriani, A. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006815.pub2 · Cited by 274 · see citing works

Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine

van Vliet, I. M., den Boer, J. A., & Westenberg, H. G. M. (1994) · Psychopharmacology · doi:10.1007/bf02244762 · Cited by 270 · see citing works

Fluvoxamine Treatment of Social Phobia (Social Anxiety Disorder): A Double-Blind, Placebo-Controlled Study

Stein, M. B., Fyer, A. J., Davidson, J. R. T., Pollack, M. H., & Wiita, B. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.756 · Cited by 263 · see citing works

Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis.

Trindade, E. M., Menon, D., Topfer, L.-A., & Coloma, C. (1998) · Europe PMC (PubMed Central) · Cited by 250 · see citing works

Intramuscular Ziprasidone, 2 mg Versus 10 mg, in the Short-Term Management of Agitated Psychotic Patients

Lesem, M. D., Zajecka, J., Swift, R. H., Reeves, K. R., & Harrigan, E. P. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0104 · Cited by 219 · see citing works

Screen for child anxiety-related emotional disorders (SCARED): Convergent and divergent validity

Monga, S., Birmaher, B. B., Chiappetta, L., Brent, D. A., Kaufman, J., Bridge, J. A., & Cully, M. (2000) · Depression and Anxiety · doi:10.1002/1520-6394(2000)12:2 · Cited by 195 · see citing works

A Review of Alprazolam Use, Misuse, and Withdrawal

Ait-Daoud, N., Hamby, A. S., Sharma, S., & Blevins, D. (2018) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000350 · Cited by 195 · see citing works

QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update

Beach, S. R., Celano, C. M., Sugrue, A. M., Adams, C. N., Ackerman, M. J., Noseworthy, P. A., & Huffman, J. C. (2017) · Psychosomatics · doi:10.1016/j.psym.2017.10.009 · Cited by 195 · see citing works

Paroxetine efficacy in the treatment of generalized anxiety disorder

Rocca, P., Fonzo, V., Scotta, M., Zanalda, E., & Ravizza, L. (1997) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1997.tb09660.x · Cited by 194 · see citing works

Alcohol or Benzodiazepine Co-involvement With Opioid Overdose Deaths in the United States, 1999-2017

Tori, M. E., Larochelle, M. R., & Naimi, T. S. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.2361 · Cited by 187 · see citing works

Practice Guideline for the Treatment of Patients With Panic Disorder

(2007) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9780890423363.51396 · Cited by 186 · see citing works

Antidepressant-induced jitteriness/anxiety syndrome: systematic review

Sinclair, L. I., Christmas, D. M., Hood, S. D., Potokar, J. P., Robertson, A. S., Isaac, A., Srivastava, S., Nutt, D., & Davies, S. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.107.048371 · Cited by 183 · see citing works

The anti-inflammatory mechanism of antidepressants – SSRIs, SNRIs

Gałecki, P., Mossakowska-Wójcik, J., & Talarowska, M. E. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.03.016 · Cited by 180 · see citing works

Effect of beta blockade and beta stimulation on stage fright.

Brantigan, C. O., Brantigan, T. A., & Joseph, N. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90592-7 · Cited by 178 · see citing works

On tyramine, food, beverages and the reversible MAO inhibitor moclobemide.

Prada, M. D., Zürcher, G., Wüthrich, I., & Haefely, W. E. (1988) · PubMed · Cited by 176 · see citing works

SSRI-induced apathy syndrome: a clinical review

BARNHART, W. J., MAKELA, E. H., & LATOCHA, M. J. (2004) · Journal of Psychiatric Practice · doi:10.1097/00131746-200405000-00010 · Cited by 170 · see citing works

Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone.

Charney, D. S., Woods, S. W., Goodman, W. K., Rifkin, B. G., Kinch, M., Aiken, B. E., Quadrino, L. M., & Heninger, G. R. (1986) · PubMed · Cited by 155 · see citing works

Moclobemide in Social Phobia

Noyes, R., Moroz, G., Davidson, J. R. T., Liebowitz, M. R., Davidson, A. B., Siegel, J., Bell, J., Cain, J. W., Curlik, S. M., Kent, T. A., et al. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199708000-00002 · Cited by 150 · see citing works

Azapirones for generalized anxiety disorder

Chessick, C. A., Allen, M. H., Thase, M. E., Batista Miralha da Cunha, A. A., Kapczinski, F., Silva de Lima, M., & dos Santos Souza, J. J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006115 · Cited by 144 · see citing works

Efficacy and Safety of Hydroxyzine in the Treatment of Generalized Anxiety Disorder

Llorca, P., Spadone, C., Sol, O., Danniau, A., Bougerol, T., Corruble, E., Faruch, M., Macher, J.-P., Sermet, É., & Servant, D. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1112 · Cited by 141 · see citing works

Escitalopram in the Treatment of Panic Disorder

Stahl, S. M., Gergel, I. P., & Li, D. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1107 · Cited by 139 · see citing works

A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder

Lader, M. H., & Scotto, J. (1998) · Psychopharmacology · doi:10.1007/s002130050731 · Cited by 133 · see citing works

Efficacy of olanzapine in social anxiety disorder: a pilot study

Barnett, S. D., Kramer, M. L., Casat, C. D., Connor, K. M., & Davidson, J. R. T. (2002) · Journal of Psychopharmacology · doi:10.1177/026988110201600412 · Cited by 125 · see citing works

Pregabalin for the treatment of generalized anxiety disorder: an update

Baldwin, D. S., Ajel, Nowak, Rafiq, & Masdrakis, V. G. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s36453 · Cited by 125 · see citing works

Adjunctive Risperidone in Generalized Anxiety Disorder

Brawman‐Mintzer, O., Knapp, R. G., & Nietert, P. J. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1016 · Cited by 124 · see citing works

Maintenance Drug Treatment of Panic Disorder: I. Results of a Prospective, Placebo-Controlled Comparison of Alprazolam and Imipramine

Schweizer, E. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820130053009 · Cited by 120 · see citing works

Paroxetine, Clomipramine, and Cognitive Therapy in the Treatment of Panic Disorder

Bakker, A., van Dyck, R., Spinhoven, P., & van Balkom, A. J. L. M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n1205 · Cited by 109 · see citing works

Chronological Milestones to Guide Drug Change

Quitkin, F. M. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830090031005 · Cited by 107 · see citing works

Panic disorder: treatment with valproate.

WOODMAN, C. L., & Noyes, R. (1994) · PubMed · Cited by 104 · see citing works

Lack of Relationship Between Long-Term Use of Benzodiazepines and Escalation to High Dosages

Soumerai, S. B., Simoni-Wastila, L., Singer, C., Mah, C., Gao, X., Salzman, C., & Ross-Degnan, D. (2003) · Psychiatric Services · doi:10.1176/appi.ps.54.7.1006 · Cited by 104 · see citing works

Fluoxetine in Social Phobia: A Double-Blind, Placebo-Controlled Pilot Study

Kobak, K. A., Greist, J. H., Jefferson, J. W., & Katzelnick, D. J. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200206000-00005 · Cited by 103 · see citing works

Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial.

Modigh, K., Westberg, P., & Eriksson, E. (1992) · PubMed · Cited by 100 · see citing works

Benzodiazepines versus placebo for panic disorder in adults

Breilmann, J., Girlanda, F., Guaiana, G., Barbui, C., Cipriani, A., Castellazzi, M., Bighelli, I., Davies, S., Furukawa, T. A., & Koesters, M. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010677.pub2 · Cited by 100 · see citing works

Pregabalin for generalized anxiety disorder

Generoso, M. B., Trevizol, A. P., Kasper, S. F., Cho, H. J., Cordeiro, Q., & Shiozawa, P. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000147 · Cited by 98 · see citing works

Diazepam versus alprazolam for the treatment of panic disorder.

Noyes, R., Burrows, G. D., Reich, J. H., Judd, F. K., Garvey, M. J., Norman, T. R., Cook, B. L., & Marriott, P. F. (1996) · PubMed · Cited by 97 · see citing works

STRESS AND TRAUMA: Psychotherapy and Pharmacotherapy for Depersonalization/Derealization Disorder.

Gentile, J. P., Snyder, M., & Gillig, P. M. (2014) · Europe PMC (PubMed Central) · Cited by 97 · see citing works

Valproic Acid and Panic Disorder

Primeau, F. J., Fontaine, R., & Beauclair, L. (1990) · The Canadian Journal of Psychiatry · doi:10.1177/070674379003500309 · Cited by 96 · see citing works

Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia

Ameringen, M. V. (1996) · Journal of Affective Disorders · doi:10.1016/0165-0327(96)00030-4 · Cited by 95 · see citing works

Lack of efficacy of carbamazepine in the treatment of panic disorder

Uhde, T. W., Stein, M. B., & Post, R. M. (1988) · American Journal of Psychiatry · doi:10.1176/ajp.145.9.1104 · Cited by 93 · see citing works

Mirtazapine versus fluoxetine in the treatment of panic disorder

Ribeiro, L. W., Busnello, J. V., Kauer‐Sant’Anna, M., Madruga, M., Quevedo, J., Busnello, E. A. D., & Kapczinski, F. P. (2001) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2001001000010 · Cited by 93 · see citing works

Superiority of Clomipramine over Imipramine in the

Modigh, K., Westberg, P., & Eriksson, E. (1992) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199208000-00007 · Cited by 92 · see citing works

Double-Blind, Placebo-Controlled Assessment of Combined Clonazepam With Paroxetine Compared With Paroxetine Monotherapy for Generalized Social Anxiety Disorder

Batten, S. V., Aslan, M., Maciejewski, P. K., & Mazure, C. M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0216 · Cited by 84 · see citing works

Pharmacotherapy for social anxiety disorder (SAnD)

Williams, T., Hattingh, C. J., Kariuki, C. M., Tromp, S. A., van Balkom, A. J., Ipser, J. C., & Stein, D. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001206.pub3 · Cited by 84 · see citing works

Mirtazapine Treatment of Social Phobia in Women

Muehlbacher, M., Nickel, M. K., Nickel, C., Kettler, C., Lahmann, C., Gil, F. P., Leiberich, P. K., Rother, N., Bachler, E., Fartacek, R. R., et al. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000186871.04984.8d · Cited by 80 · see citing works

Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials

Maneeton, N., Maneeton, B., Woottiluk, P., Likhitsathian, S., Suttajit, S., Boonyanaruthee, V., & Srisurapanont, M. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s89485 · Cited by 80 · see citing works

iPlasticity: Induced juvenile‐like plasticity in the adult brain as a mechanism of antidepressants

Umemori, J., Winkel, F., Didio, G., Llach Pou, M., & Castrén, E. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12683 · Cited by 80 · see citing works

A Double-Blind Randomized Controlled Trial of Augmentation and Switch Strategies for Refractory Social Anxiety Disorder

Pollack, M. H., Ameringen, M. V., Simon, N. M., Worthington, J. W., Hoge, E. A., Keshaviah, A. P., & Stein, M. B. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12101353 · Cited by 78 · see citing works

Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients

Asnis, G. M., Hameedi, F. A., Goddard, A. W., Potkin, S. G., Black, D. W., Jameel, M., Desagani, K., & Woods, S. W. (2001) · Psychiatry Research · doi:10.1016/s0165-1781(01)00265-7 · Cited by 76 · see citing works

Clonazepam in the Treatment of Panic Disorder With or Without Agoraphobia

Rosenbaum, J. F., Moroz, G., & Bowden, C. L. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199710000-00008 · Cited by 75 · see citing works

Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks.

Buigues, J., & Vallejo, J. (1987) · PubMed · Cited by 71 · see citing works

Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships

MAVISSAKALIAN, M. R., & Perel, J. M. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.5.673 · Cited by 69 · see citing works

Efficacy, Safety, and Gradual Discontinuation of Clonazepam in Panic Disorder

Moroz, G., & Rosenbaum, J. F. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0907 · Cited by 69 · see citing works

Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety

Sheehan, D. V., McElroy, S. L., Harnett-Sheehan, K., Keck, P. E., Janavs, J., Rogers, J., Gonzalez, R., Shivakumar, G., & Suppes, T. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.10.005 · Cited by 69 · see citing works

Olanzapine Augmentation in Treatment-Resistant Panic Disorder

Sepede, G., Berardis, D. D., Gambi, F., Campanella, D., Rovere, R. L., D'Amico, M., Cicconetti, A., Penna, L. L., Peca, S., Carano, A., et al. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000195108.01898.17 · Cited by 68 · see citing works

Efficacy of pregabalin in generalized social anxiety disorder

Feltner, D. E., Liu-Dumaw, M., Schweizer, E. E., & Bielski, R. (2011) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32834519bd · Cited by 67 · see citing works

Mirtazapine treatment of Generalized Anxiety Disorder: a fixed dose, open label study

Gambi, F., Berardis, D. D., Campanella, D., Carano, A., Sepede, G., Salini, G., Mezzano, D., Cicconetti, A., Penna, L. L., Salerno, R. M., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105056527 · Cited by 67 · see citing works

The Alprazolam to Clonazepam Switch for the Treatment of Panic Disorder

Herman, J. B., Rosenbaum, J. F., & Brotman, A. W. (1987) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198706000-00012 · Cited by 63 · see citing works

How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database

Baldwin, D. S., Stein, D. J., Dolberg, O. T., & Bandelow, B. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1019 · Cited by 63 · see citing works

The effect of propranolol versus placebo on resident surgical performance.

(1998) · PubMed Central · Cited by 61 · see citing works

Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: A systematic review and meta-analysis

Pae, C., Wang, S., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Serretti, A. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.02.017 · Cited by 60 · see citing works

Pharmacological and psychological interventions for generalized anxiety disorder in adults: A network meta-analysis

Chen, T.-R., Huang, H., Hsu, J., Ouyang, W.-C., & Lin, K. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.08.014 · Cited by 60 · see citing works

Quetiapine as monotherapy for social anxiety disorder: A placebo-controlled study

Vaishnavi, S., Alamy, S., Zhang, W., Connor, K. M., & Davidson, J. R. T. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.06.027 · Cited by 59 · see citing works

Pharmacological treatments for social anxiety disorder in adults: a systematic review and network meta-analysis

Williams, T., McCaul, M., Schwarzer, G., Cipriani, A., Stein, D. J., & Ipser, J. (2020) · Acta Neuropsychiatrica · doi:10.1017/neu.2020.6 · Cited by 59 · see citing works

The galway study of panic disorder I:

Fahy, T. J., O'Rourke, D., Brophy, J., Schazmann, W., & Sciascia, S. (1992) · Journal of Affective Disorders · doi:10.1016/0165-0327(92)90094-m · Cited by 58 · see citing works

Lorazepam Vs. Alprazolam in the Treatment of Panic Disorder

Schweizer, E. E., Pohl, R. B., Balon, R., Fox, I., Rickels, K., & Yeragani, V. (1990) · Pharmacopsychiatry · doi:10.1055/s-2007-1014489 · Cited by 58 · see citing works

Moclobemide and fluoxetine for panic disorder

Tiller, J. W. G., Bouwer, C., Behnke, K., & For the International Panic Disorder Study Group (1999) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/pl00014164 · Cited by 56 · see citing works

Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study

Schutters, S. I. J., van Megen, H. J. G. M., Veen, J. F. V., Denys, D. A. J. P., & Westenberg, H. G. M. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32833a4d71 · Cited by 56 · see citing works

Psychopharmacologic validation of atypical depression.

Liebowitz, M. R., Quitkin, F. M., STEWART, J. D., McGrath, P. J., Harrison, W. M., Rabkin, J. G., TRICAMO, E., Js, M., & Klein, D. F. (1984) · PubMed · Cited by 55 · see citing works

Switching antidepressants for treatment-resistant major depression.

Marangell, L. B. (2001) · PubMed · Cited by 51 · see citing works

Benzodiazepine treatment can impair or spare extinction, depending on when it is given

Hart, G., Panayi, M. C., Harris, J. A., & Westbrook, R. F. (2014) · Behaviour Research and Therapy · doi:10.1016/j.brat.2014.02.004 · Cited by 51 · see citing works

An open trial of nefazodone in adult patients with generalized anxiety disorder.

Dw, H., Reimherr, F. W., Re, S., Ch, H., & Rust, C. (1996) · PubMed · Cited by 51 · see citing works

An Open-Label Trial of Aripiprazole Augmentation for Treatment-Resistant Generalized Anxiety Disorder

Menza, M. A., Dobkin, R. D., & Marín, H. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000248620.34541.bc · Cited by 49 · see citing works

Mirtazapine in the treatment of panic disorder: an open-label trial

Sarchiapone, M., Amore, M., Risio, S. D., Carli, V., Faia, V., Poterzio, F., Balista, C., Camardese, G., & Ferrari, G. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000047780.24295.3e · Cited by 49 · see citing works

A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder.

Bystritsky, A., Kerwin, L. E., Feusner, J. D., & Vapnik, T. (2008) · PubMed · Cited by 48 · see citing works

Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder

Greist, J. H., Liu-Dumaw, M., Schweizer, E. E., & Feltner, D. E. (2011) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283491fd5 · Cited by 46 · see citing works

A Double-Blind, Placebo-Controlled, Multicenter Study

Pecknold, J. C., Luthe, L., Munjack, D. J., & Alexander, P. E. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199410000-00005 · Cited by 46 · see citing works

Next-Step Strategies for Panic Disorder Refractory to Initial Pharmacotherapy: A 3-Phase Randomized Clinical Trial

Simon, N. M., Otto, M. W., Worthington, J. J., Hoge, E. A., Thompson, E. H., LeBeau, R. T., Moshier, S. J., Zalta, A. K., & Pollack, M. H. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04485blu · Cited by 45 · see citing works

Open‐Label Support for Duloxetine for the Treatment of Panic Disorder

Simon, N. M., Kaufman, R. E., Hoge, E. A., Worthington, J. J., Herlands, N. N., Owens, M. E., & Pollack, M. H. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00076.x · Cited by 43 · see citing works

Treatment of Poststroke Generalized Anxiety Disorder Comorbid With Poststroke Depression: Merged Analysis of Nortriptyline Trials

Kimura, M., Tateno, A., & Robinson, R. G. (2003) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200305000-00009 · Cited by 43 · see citing works

The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder

Krüger, M. B., & Dahl, A. A. (1999) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/pl00014163 · Cited by 43 · see citing works

Sertraline Versus Imipramine Treatment of Comorbid Panic Disorder and Major Depressive Disorder

Lepola, U. M., Arató, M., Zhu, Y., & Austin, C. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0606 · Cited by 41 · see citing works

Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders

Gao, K., Sheehan, D. V., & Calabrese, J. R. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.37 · Cited by 41 · see citing works

The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period

Boshuisen, M. L., Slaap, B. R., Vester-Blokland, E., & den Boer, J. A. (2001) · International Clinical Psychopharmacology · doi:10.1097/00004850-200111000-00008 · Cited by 40 · see citing works

Efficacy of Quetiapine in Generalized Social Anxiety Disorder

Schutters, S. I. J., van Megen, H. J. G. M., & Westenberg, H. G. M. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0420b · Cited by 39 · see citing works

A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia.

Bakish, D., Cl, H., Filteau, M., Charbonneau, Y., Fraser, G. L., West, D., Thibaudeau, C. A., & Raine, D. (1996) · PubMed · Cited by 39 · see citing works

Comparative efficacy and acceptability of first-line drugs for the acute treatment of generalized anxiety disorder in adults: A network meta-analysis

He, H., Xiang, Y., Gao, F., Bai, L., Gao, F., Fan, Y., Lyu, J., & Ma, X. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.08.009 · Cited by 39 · see citing works

Ziprasidone Treatment of Refractory Generalized Anxiety Disorder

Lohoff, F. W., Etemad, B., Mandos, L. A., Gallop, R., & Rickels, K. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181d21951 · Cited by 38 · see citing works

Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder.

Tiller, J. W. G., Bouwer, C., & Behnke, K. (1997) · PubMed · Cited by 37 · see citing works

A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder

Sasson, Y., Iancu, I., Fux, M., Taub, M., Dannon, P. N., & Zohar, J. (1999) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(98)00024-8 · Cited by 37 · see citing works

Beta-Adrenergic Blocking Drugs in Anxiety and Stress

Noyes, R. (1985) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30713-5 · Cited by 35 · see citing works

Bupropion Sustained Release for Panic Disorder

Simon, N. M., Emmanuel, N. P., Emmanuel, N., Worthington, J. J., Ballenger, J. F., Korbly, N. B., Worthington, J. J., Pollack, M. H., Kinrys, G., Farach, F. J., et al. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4163 · Cited by 34 · see citing works

Mirtazapine in social anxiety disorder: a pilot study

Veen, J. F. V., van Vliet, I. M., & Westenberg, H. G. M. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200211000-00008 · Cited by 34 · see citing works

Long-term experience with clonazepam in patients with a primary diagnosis of panic disorder.

Worthington, J. J., Pollack, M. H., Otto, M. W., McLean, R. Y. S., Moroz, G., & Rosenbaum, J. F. (1998) · PubMed · Cited by 33 · see citing works

Reversible monoamine oxidase-A inhibitors in panic disorder.

Bakish, D., Saxena, B., Bowen, R., & D’Souza, J. (1993) · PubMed · Cited by 33 · see citing works

A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study

Prosser, J. M., Yard, S. S., Steele, A., Cohen, L. J., & GALYNKER, I. I. (2009) · BMC Psychiatry · doi:10.1186/1471-244x-9-25 · Cited by 32 · see citing works

Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine

Nierenberg, A. A., Loft, H., & Olsen, C. K. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.02.006 · Cited by 32 · see citing works

The efficacy of milnacipran in panic disorder: an open trial

Blaya, C., Seganfredo, A. C. G., Dornelles, M., Torres, M., Paludo, A. P., Heldt, E., & Manfro, G. G. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32802c7bf5 · Cited by 30 · see citing works

Adjunctive Risperidone in the Treatment of Generalized Anxiety Disorder: A Double-Blind, Prospective, Placebo-Controlled, Randomized Trial

Pandina, G., PhD, Canuso, C. M., MD, Turkoz, I., MS, Kujawa, M. J., MD, PhD, Mahmoud, R. A., et al. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4108 · Cited by 30 · see citing works

Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder

Liebowitz, M. R., Careri, J. M., Blatt, K., Draine, A., Morita, J., Moran, M., & Hanover, R. (2017) · Depression and Anxiety · doi:10.1002/da.22702 · Cited by 28 · see citing works

Benzodiazepine misuse in adults with alcohol use disorder: Prevalence, motives and patterns of use

McHugh, R. K., Votaw, V. R., Taghian, N. R., Griffin, M. L., & Weiss, R. D. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2020.108061 · Cited by 28 · see citing works

Involvement of mitochondrial dysfunction in nefazodone-induced hepatotoxicity

Silva, A. M., Barbosa, I. A., Seabra, C., Beltrão, N., Pereira-Santos, A. R., Vega‐Naredo, I., Oliveira, P. J., & Cunha‐Oliveira, T. (2016) · Food and Chemical Toxicology · doi:10.1016/j.fct.2016.06.001 · Cited by 27 · see citing works

Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: A meta-analysis

Zareifopoulos, N., & Dylja, I. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.01.016 · Cited by 26 · see citing works

Moclobemide for anxiety disorders

Tiller, J. W. G., Bouwer, C., & Behnke, K. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199710006-00006 · Cited by 26 · see citing works

Efficacy of Open-Label Nefazodone Treatment in Patients With Panic Disorder

Papp, L. A., Coplan, J. D., Martinez, J. M., de Jesus, M., & Gorman, J. M. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200010000-00009 · Cited by 25 · see citing works

Double-blind comparison of 30 and 60 mg tranylcypromine daily in patients with panic disorder comorbid with social anxiety disorder

Nardi, A. E., Lopes, F. L., Valença, A. M., Freire, R. C. R., Nascimento, I., Veras, A. B., Mezzasalma, M. A., Neto, V. L. D. M., Soares‐Filho, G. L., King, A. L. S., et al. (2009) · Psychiatry Research · doi:10.1016/j.psychres.2008.06.025 · Cited by 24 · see citing works

Pharmacokinetic Comparison of Two Albendazole Dosage Regimens in Patients with Neurocysticercosis

Sánchez, M., Suástegui, R., González‐Esquivel, D. F., Sotelo, J., & Jung, H. (1993) · Clinical Neuropharmacology · doi:10.1097/00002826-199302000-00009 · Cited by 23 · see citing works

Treatment of Generalized Anxiety Disorder with Gabapentin

Markota, M., & Morgan, R. J. (2017) · Case Reports in Psychiatry · doi:10.1155/2017/6045017 · Cited by 23 · see citing works

An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder

Shah, A., & Northcutt, J. (2018) · Annals of General Psychiatry · doi:10.1186/s12991-018-0190-6 · Cited by 23 · see citing works

The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An Algorithm for Generalized Anxiety Disorder

Abejuela, H. R., & Osser, D. N. (2016) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000098 · Cited by 22 · see citing works

Clomipramine Treatment for Generalized Anxiety Disorder

Wingerson, D. K., NGUYEN, C., & Roy‐Byrne, P. (1992) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199206000-00013 · Cited by 20 · see citing works

Duloxetine for the Treatment of Generalized Social Anxiety Disorder: A Preliminary Randomized Trial of Increased Dose to Optimize Response

Simon, N. M., Worthington, J. J., Moshier, S. J., Marks, E. H., Hoge, E. A., Brandes, M., Delong, H., & Pollack, M. H. (2010) · CNS Spectrums · doi:10.1017/s1092852900000365 · Cited by 19 · see citing works

A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Vilazodone in Generalized Social Anxiety Disorder

Careri, J. M., Draine, A., Hanover, R., & Liebowitz, M. R. (2015) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.15m01831 · Cited by 19 · see citing works

Clomipramine treatment for generalized anxiety disorder.

Wingerson, D. K., Nguyen, C., & Roy‐Byrne, P. (1992) · PubMed · Cited by 18 · see citing works

Self-Reported Sedation Profile of Quetiapine Extended-Release and Quetiapine Immediate-Release During 6-Day Initial Dose Escalation in Bipolar Depression: A Multicenter, Randomized, Double-Blind, Phase IV Study

Riesenberg, R. A., Baldytcheva, I., & Datto, C. J. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.09.002 · Cited by 18 · see citing works

A comprehensive model of predictors of suicide attempt in individuals with panic disorder: Results from a national 3-year prospective study

Scheer, V., Blanco, C., Olfson, M., Lemogne, C., Airagnes, G., Peyre, H., Limosin, F., & Hoertel, N. (2020) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2020.09.006 · Cited by 12 · see citing works

Tricyclic Antidepressant Toxicity

Khalid, M. M., & Waseem, M. (2019) · StatPearls · Cited by 8 · see citing works

Controlled-release fluvoxamine in obsessive-compulsive disorder and social phobia

Owen, R. T. (2008) · Drugs of today · doi:10.1358/dot.2008.44.12.1299291 · Cited by 7 · see citing works

Use of beta-blocking agents to reduce the stress of presentation at an international cardiology meeting: Results of a survey

Gossard, D., Dennis, C. A., & DeBusk, R. F. (1984) · The American Journal of Cardiology · doi:10.1016/0002-9149(84)90341-2 · Cited by 4 · see citing works

Untitled work

Lorberbaum (1999) · doi:10.1002/(sici)1520-6394(1999)10:3

Long-term use of benzodiazepines in chronic insomnia: a European perspective

Soyka, M., Wild, I., Caulet, B., Leontiou, C., Lugoboni, F., & Hajak, G. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1212028 · Cited by 104 · see citing works

Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits

Brunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09499-2 · Cited by 51 · see citing works

Efficacy and Safety of Psychedelics in Treating Anxiety Disorders

Feulner, L., Sermchaiwong, T., Rodland, N., & Galarneau, D. W. (2023) · Ochsner Journal · doi:10.31486/toj.23.0076 · Cited by 28 · see citing works

Pharmacotherapy for Anxiety Disorders.

O’Leary, K. B., & Khan, J. S. (2024) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2024.04.012 · Cited by 22 · see citing works

Systematic review on the anxiolytic and hypnotic effects of flower extracts in in vivo pre‐clinical studies published from 2010 to 2020

Meneses, C. S., Valdés, M., Garrido‐Suárez, B. B., & Garrido, G. (2023) · Phytotherapy Research · doi:10.1002/ptr.7830 · Cited by 16 · see citing works

Experiential Avoidance as a Transdiagnostic Mediator in the Relationship Between Intolerance of Uncertainty, Maladaptive Perfectionism, and Psychiatric Symptoms: Structural and Causal Mediation Analyses in a Clinical Sample

Gerdan, G., & Şalcıoğlu, E. (2025) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.70102 · Cited by 10 · see citing works

Reversing anxiety by targeting a stress-responsive signaling pathway

Pandey, S., Han, W., Li, J., Shepard, R. D., Wu, K., Castellano, D., Tian, Q., Dong, L., Li, Y., & Lü, W. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2400078121 · Cited by 10 · see citing works

Using Natural Language Processing to develop risk-tier specific suicide prediction models for Veterans Affairs patients

Levis, M., Dimambro, M., Levy, J., & Shiner, B. R. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.09.031 · Cited by 9 · see citing works

Gingerols and Shogaols of Zingiber officinale var. sunti Valeton as Potential Allosteric Agonists of Human GABAA Receptor by in silico Pharmacology Approach

Kuswandani, F., Wilar, G., Wahyuni, I. S., Megantara, S., Pitaloka, D. A. E., Levita, J., & Jiranusornkul, S. (2025) · Journal of Experimental Pharmacology · doi:10.2147/jep.s524890 · Cited by 7 · see citing works

Chitosan-Based Nanoparticles for Nose-to-Brain Drug Delivery: A Real Path toward Effective CNS Therapy?

Riani, L. R., Seno, G. F. B., Silva, D. M. E., Toledo, C. R., de Paiva, M. R. B., Santos, J. S., Fabri, R. L., Pittella, F., & Tavares, G. D. (2026) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.6c00137 · Cited by 8 · see citing works

β-Carboline (FG-7142) modulates fear but not anxiety-like behaviour in zebrafish

Scatterty, K. R., & Hamilton, T. J. (2024) · Scientific Reports · doi:10.1038/s41598-023-51072-6 · Cited by 6 · see citing works

Cannabidiol in anxiety disorders: Current and future perspectives

Simei, J. L. Q., Souza, J. D. R., Lisboa, J. R., Guimarães, F. S., & Crippa, J. A. S. (2024) · International review of neurobiology · doi:10.1016/bs.irn.2024.05.003 · Cited by 7 · see citing works

Examining the relationship between long working hours and the use of prescription sedatives among U.S. workers

Ezekekwu, E. U., Johnson, C., Karimi, S. M., Antimisiaris, D. E., & Lorenz, D. (2023) · Sleep Medicine · doi:10.1016/j.sleep.2023.06.026 · Cited by 5 · see citing works

Astrocytes in Rodent Anxiety-Related Behavior: Role of Calcium and Beyond

Gómez-Gonzalo, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062774 · Cited by 4 · see citing works

Exploring the impact of MDMA and oxytocin ligands on anxiety and social responses: A comprehensive behavioural and molecular study in the zebrafish model

Maciąg, M., Doszyn, O., Wnorowski, A., Zmorzyńska, J., & Budzyńska, B. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251324596 · Cited by 4 · see citing works

Effects of app delivered self hypnosis on stress management

Tran, N., Saperia, C., Neri, E., Jo, B., Kim, B., Zewde, N., Nouriani, B., Kinderman, C., Jagielo, A., Faerman, A., et al. (2025) · npj Digital Medicine · doi:10.1038/s41746-025-02182-0 · Cited by 3 · see citing works

Falls in a single brain rehabilitation center: a 3-year retrospective chart review

Choo, Y. J., Moon, J. S., Lee, G. W., Park, W.-T., & Chang, M. C. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1519555 · Cited by 3 · see citing works

Pharmacological strategies for treating social anxiety disorder in adults: a systematic review of studies published since 2015

Andreoli, G., Kasch, C., Lindsay, C. E., & Hofmann, S. G. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2604303 · Cited by 2 · see citing works

Treating Neuropsychiatric Conditions in Pediatric Epilepsy: Practical Considerations

Ertenu, D. D., & Salpekar, J. A. (2025) · Epiliepsy currents/Epilepsy currents · doi:10.1177/15357597251350031 · Cited by 2 · see citing works

Efficacy, suicidality, tolerability, and acceptability of selective serotonin reuptake inhibitors and serotonin–norepinephrine reuptake inhibitors for children and adolescents with anxiety disorders: a systematic review and meta-analysis

Karawekpanyawong, N., Charnsil, C., Suttajit, S., & Srisurapanont, M. (2025) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000599 · Cited by 2 · see citing works

Pharmaceutical compounds and their toxicity to marine organisms: Emerging contaminants and innovative strategies to reduce pharmaceutical pollution – A review and meta-analysis

Amin, M. F., & Rahman, M. S. (2026) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2026.110519 · Cited by 4 · see citing works

Management of post-traumatic stress disorder: a review of anxiety disorders and PTSD

Skosana, P., Mokhele, S., Andrew, J., Zikalala-Mabope, L., Lentsoane, P., & Abraham, V. (2024) · SA pharmaceutical journal. · doi:10.36303/sapj.0746 · Cited by 2 · see citing works

Other Psychiatric Disorders, Psychosocial Factors, Sleep, and Pain

Bair, M. J., & Owen‐Smith, A. A. (2024) · Oxford University Press eBooks · doi:10.1093/9780197675250.003.0006 · Cited by 3 · see citing works

Callistemon viminalis extracts: dual action on anxiety and neuroprotection via neuroinflammatory and serotonergic pathways

Kumari, N., Mittal, A., Rana, A., & Sharma, A. K. (2025) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-024-01748-x · Cited by 1 · see citing works

An attempt at conceptualizing a multidimensional body-brain nature of stress reduction

Kosma, M. (2026) · Academia Mental Health and Well-Being · doi:10.20935/mhealthwellb8261 · Cited by 1 · see citing works

Chemogenetic inhibition of ventral hippocampal inputs to the basal amygdala reduces anxiety-like behavior

Tiwari, P., Vuruputuri, R. M., Mukherjee, S., & Vaidya, V. A. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.153907 · Cited by 1 · see citing works

From Subjective to Objective: The Bedside Value of HRV in AssessingChronic Pain Complicated by Emotionaland Sleep Issues

Hu, J., Xiao, Y., Ma, G., Yao, B., Li, J., An, H., Wang, G., & Chen, Y. (2026) · Applied Psychophysiology and Biofeedback · doi:10.1007/s10484-026-09797-3 · Cited by 1 · see citing works

Acute Toxicity and Anxiolytic Activity Screening of Hydroalcoholic Leaf Extracts of Bryophyllum pinnatum, Terminalia catappa and Tapinanthus dodoneifolius Growing on Terminalia catappa Tree in MIce

Umarudeen, A. M., Magaji, M. G., Khan, F., & Abubakar, A. (2023) · International Neuropsychiatric Disease Journal · doi:10.9734/indj/2023/v19i3374 · Cited by 1 · see citing works

Authors’ Reply to Pande et al. Comment on “Extended-Release Viloxazine Compared to Atomoxetine for Attention Deficit Hyperactivity Disorder”

Price, M. Z., & Price, R. L. (2023) · CNS Drugs · doi:10.1007/s40263-023-01035-2 · Cited by 1 · see citing works

Use of Anxiolytics during Professional Examinations among Medical and Allied Students of Azra Naheed Medical College, Lahore

Zahid, M., Latif, M. Z., & Qureshi, M. A. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs2022161236

Current Evidence of Cannabidiol's Potential as an Anxiolytic Agent

Rossi, G. N., Reis, J. A. S., Hallak, J. E. C., & SANTOS, R. G. D. (2023) · Psychiatric Annals · doi:10.3928/00485713-20230515-02

A cannabidiol (CBD) oral lipid-based nanoemulsion induces anxiolytic- and panicolytic-like effects and increases delta-FosB immunoreactivity in serotonergic cells of the dorsal raphe lateral wingsPreprint

Rosário, B. D. A., de Lima, M. P., Vieira, M. G., de Aquino, P. É. A., Viana, G. S. D. B., Silveira, E. R., de Brito, D. H. A., Zampieri, D., Lemes, J. A., de Nazaré, M. D. F. S., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3705796/v1

The efficacy of integrated transdiagnostic treatment in reducing worry, anxiety, depressive and emotional regulation in patients with generalized anxiety disorder

Kolah-Zari, S., Mohammadi, A., & Rezaei, F. (2024) · Shenakht Journal of Psychology and Psychiatry · doi:10.32598/shenakht.10.5.58

The state of anxiety treatments for adolescents and adults down syndrome: Results from a scoping rapid review

Fodstad, J. C., Jones, L. B., Iticovici, M. S., Russell, R. M., Bullington, M. R. S., & Meudt, E. (2024) · Journal of Mood and Anxiety Disorders · doi:10.1016/j.xjmad.2024.100056

NONSPECIFIC PROTECTIVE AND ADAPTIVE REACTION OF THE BODY IN THE DEVELOPMENT OF PANIC ATTACKS AND PRIMARY PREVENTION OF CARDIOVASCULAR DISEASESPreprint

Vodopianov, V. A. (2024) · doi:10.14293/pr2199.000698.v1

Evaluation of Zinc acetate in decreasing anxiety like behavior in Swiss Albino Mice using behavior model

Sasikala, G., Praveena, R., & Meeradevi, A. (2024) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2024.00183

Urinary Incontinence Associated with Sertraline use in a Young SSRI-Naí¯ve Female Patient: a Case Report

Elissa, A. (2024) · Jurnal Psikiatri Surabaya · doi:10.20473/jps.v13i1.45369

Pharmacological Treatment of Anxiety Disorders: Current and Novel Targets

Chatzittofis, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-56798-8_5

“I Am Not Addicted to Valium”

Gibfried, M., & Grossberg, G. T. (2024) · Cambridge University Press eBooks · doi:10.1017/9781108630344.031

Pregabalin misuse: a case report

Hosseini, S. H., Ghazvini, H., Tamijani, S. M. S., & Rafaiee, R. (2025) · Journal of Substance Use · doi:10.1080/14659891.2025.2460788

Treatment

Steven, H., Schwartz, Z. A., & Blum, A. W. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009280099.014

A cannabidiol (CBD) lipid-based nanoemulsion induces anxiolytic- and panicolytic-like effects and increases FosB/deltaFosB immunoreactivity in serotonergic cells of the dorsal raphe

Rosário, B. D. A., de Lima, M. P., Vieira, M. G., Leite, L. G., de Aquino, P. É. A., Viana, G. S. D. B., Silveira, E. R., de Brito, D. H. A., Zampieri, D., Ricardo, N. M. P. S., et al. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149791

Prescription Analysis of Antihistamines’ Use in Patients With Moderate to Severe Burns

Karim, A., Karim, N., Shah, S., Syed, R., Akbar, Z., Marzook, F. A., Song, J., Golovko, G., Wolf, S. E., & Ayadi, A. E. (2026) · Journal of Burn Care & Research · doi:10.1093/jbcr/irag007

Anxiety during perimenopause: a qualitative study of lived experiences

McElhany, K., Dishman, D., Metcalf, C. A., & Beauchamp, J. E. S. (2026) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002744

Effect of Jasminum sambac on Stress-Induced Anxiety in Mice

Dangi, N., Sharma, A., & Kaushal, B. (2026) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v16i2.7573

Anxiolytic and Antidepressant‐Like Effects of a Probiotic Mixture HMLH123 Potentially via the Serotonergic Pathway in Wistar Rats

Rosas-Sánchez, G. U., Germán-Ponciano, L. J., Nápoles-Medina, A. Y., Aguilar‐Uscanga, B. R., Flores-Soto, M. E., & Soria-Fregozo, C. (2026) · Behavioural Neurology · doi:10.1155/bn/6680245

Association of Antidepressant and/or Benzodiazepine Use With Cannabis Frequency and Differences by Sex in Primary Care Patients With Depression and/or Anxiety

Setrakian, N., Gelberg, L., Gorbach, P. M., Seamans, M. J., SHOPTAW, S. J., & Javanbakht, M. (2026) · Depression and Anxiety · doi:10.1155/da/5205059

Cannabidiol at the crossroads: panacea, placebo, or problem?

Bidwell, L. C., & Vandrey, R. G. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02415-0

Functional neuroimaging of Cannabidiol in stress and anxiety: a systematic review

Rutledge, O., Goyette, R., Wang, K. L., Park, M. S., & Gabrieli, J. D. E. (2026) · Frontiers in Neuroimaging · doi:10.3389/fnimg.2026.1860919

Combined aromatherapy and music or sound for emotional distress: a systematic review of controlled studies published between 2019 and 2026

Zhai, H., Chen, X., Lv, D., Yin, A. J.-W., Zhang, W., Wang, Y., Li, Q., & Lin, Z. (2026) · Frontiers in Psychology · doi:10.3389/fpsyg.2026.1955987

The Pharmacologic Treatment of Anxiety Disorders: A Review of Progress

Ravindran, L. N., & Stein, M. B. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10r06218blu · Cited by 317 · see citing works

Network analyses to rank pharmacological treatments for generalised anxiety disorder

Bandelow, B., & Wedekind, D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32180-9 · Cited by 2 · see citing works

Evidence-based guidelines for pharmacological treatment of anxiety disorders

Baldwin, D. S., Anderson, I. M., Nutt, D., Bandelow, B., Bond, A. J., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M. R. J., Scott, J. L., et al. (2013)

Current and Novel Psychopharmacological Drugs for Anxiety Disorders

Bandelow, B. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9705-0_19 · Cited by 103 · see citing works

Treatment of anxiety disorders

Bandelow, B., Michaelis, S., & Wedekind, D. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.2/bbandelow · Cited by 811 · see citing works